X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

IMPL

Closed

Impel Neuropharma Inc

0.0157
-0.0043 (-21.50%)
Last Update: 16 Feb 2024 17:30:00
Yesterday: 0.02
Day's Range: 0.0137 - 0.02
Send
When Written:
 
1.45
Impel NeuroPharma Inc. is a biopharmaceutical company that focuses on developing transformative therapies for patients living with central nervous system (CNS) disorders. The company was founded in 2008 and is headquartered in Seattle, Washington.

Impel NeuroPharma's proprietary Precision Olfactory Delivery (POD) technology enables the delivery of therapeutic molecules to the brain through the olfactory region of the nasal cavity. This approach has the potential to bypass the blood-brain barrier and improve the efficacy of CNS therapies.

The company's pipeline includes treatments for migraine, Parkinson's disease, and acute agitation in patients with schizophrenia or bipolar I disorder. Its lead product candidate, INP104, is a drug-device combination product for the acute treatment of migraine. The company has also partnered with other pharmaceutical companies to develop and commercialize certain products.

Impel NeuroPharma has raised over $230 million in funding from investors, including venBio Partners, 5AM Ventures, and venBio Global Strategic Fund. The company went public in July 2020 and is listed on the NASDAQ under the ticker symbol "IMPL".

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.209
X